GLP-1 receptor agonists (GLP-1s), including semaglutide, tirzepatide, and liraglutide, are increasingly used for weight management and show promise for people living with HIV (PLWH). While these medications are generally safe, PLWH may face additional considerations when using them due to how GLP-1s function and interact with antiretroviral therapy (ART). GLP-1s slow gastric emptying and suppress appetite, which may affect ART absorption; gastrointestinal side effects such as nausea or vomiting may also interfere with consistent ART dosing.

This infographic from Fair Health draws on data from its NPIC database—over 47 billion commercial medical and dental claims—to highlight rising trends in sexually transmitted disease (STD) diagnoses across various demographics in the U.S. between 2020 and 2023. The visuals show that overall STD diagnoses increased significantly, led by notable rises in syphilis, gonorrhea, and HIV/AIDS.

Tuberculosis (TB) remains the world’s deadliest infectious disease and a major treatment challenge, especially in cases resistant to standard therapies. A new AI-powered tool developed by Tufts University researchers, called DECIPHAER (Decoding Cross-Modal Information of Pharmacologies via Autoencoders), seeks to advance TB treatment by elucidating exactly how drugs kill the bacterium at the cellular and molecular levels.

Tuberculosis (TB), a contagious bacterial infection primarily affecting the lungs, remains a health risk in the U.S. Though cases declined for decades, recent increases — including ~10,347 cases in early data from 2024 — suggest testing and treatment of latent TB is needed more than ever.  Testing is crucial both for diagnosing latent TB (where bacteria are present but symptoms are absent) and active TB disease (which is contagious and manifests symptoms).